Back

Muscle specific translational control of Cand2 by mTORC1 regulates adverse cardiac remodeling

Gorska, A.; Sandmann, C.; Riechert, E.; Hofmann, C.; Malovrh, E.; Varma, E.; Kmietczyk, V.; Juergensen, L.; Kamuf-Schenk, V.; Stroh, C.; Furkel, J.; Konstandin, M.; Sticht, C.; Boileau, E.; Dieterich, C.; Katus, H. A.; Doroudgar, S.; Völkers, M.

2020-12-01 molecular biology
10.1101/2020.11.29.403196 bioRxiv
Show abstract

The mechanistic target of rapamycin (mTOR) is a key regulator of pathological remodeling in the heart by activating ribosomal biogenesis and mRNA translation. Inhibition of mTOR in cardiomyocytes is protective, however, a detailed role of mTOR in translational regulation of specific mRNA networks in the diseased heart is largely unknown. A cardiomyocyte genome-wide sequencing approach was used to define mTOR-dependent post-transcriptional gene expression control at the level of mRNA translation. This approach identified the muscle-specific protein Cullin-associated NEDD8-dissociated protein 2 (Cand2) as a translationally upregulated gene, dependent on the activity of mTOR. Deletion of Cand2 protects the myocardium against pathological remodeling. Mechanistically, we found that Cand2 links mTOR signaling to pathological cell growth by increasing Grk5 protein expression. Our data suggest that cell-type-specific targeting of mTOR might have therapeutic value for adverse pathological cardiac remodeling.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.